The CDC recently reported that only about half of US teenager girls have received the safe and effective quadrivalent HPV vaccine (HPV4), a disappointing level of vaccine uptake. Moreover, this rate hasn’t changed over the past three years, despite significant efforts to increase the awareness and effectiveness of the vaccine amongst teenagers. Even worse news in this report is that only about one-third of teenage girls have been fully immunized with all three doses.
HPV quadrivalent vaccine, also known as Gardasil (or Silgard in Europe), is marketed by Merck & Co., usually for vaccination of teenage girls (with an increasing number of boys). The vaccine prevents the transmission of certain types (pdf) of human papillomavirus (HPV), specifically types 6, 11, 16 and 18.
HPV types 16 and 18 cause approximately 70% of cervical cancers, and caused most HPV-induced anal (95% linked to HPV), vulvar (50% linked), vaginal (65% linked), oropharyngeal (60% linked) and penile (35% linked) cancers. These cancers, mostly related to HPV, can be prevented as long as you can prevent the HPV infection from ever happening, which usually happens through genital contact, most often during vaginal and anal sex.
HPV may also be passed on during oral sex and genital-to-genital contact. HPV can be passed on between straight and same-sex partners—even when the infected partner has no signs or symptoms. Approximately 79 million Americans, most in their late teens and early 20′s, are infected with HPV, and about 14 million people become infected each year in the USA. Continue reading “HPV vaccinations lagging despite strong safety and effectiveness”